A randomized double-blind study assessing 4 versus 8 mg. doxazosin for benign prostatic hyperplasia

Journal of Urology

Volumn 162, Issue 5, 1999, Pages 1629-1632

  MacDiarmid, Scott A ^a   Emery, Robert T ^a   Ferguson, Scott F ^a   McGuirt Franklin, Rebecca ^a   McIntyre, William J ^a   Johnson, Don E ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Doxazosin; Prostatic hyperplasia; Treatment outcome

Indexed keywords

DOXAZOSIN;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; HUMAN; IMPOTENCE; MAJOR CLINICAL STUDY; MALE; NAUSEA; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; SCORING SYSTEM; TREATMENT OUTCOME; VERTIGO;

EID: 0032851611     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)68183-9     Document Type: Article

References (7)

1. Caine, M.: The present role of alpha adrenergic blockers in the treatment of benign prostatic hyperplasia. J. Urol., 136: 1, 1986.
2. Janknegt, R. A. and Chapple, C. R.: Efficacy and safety of the alpha-1 blocker doxazosin in the treatment of benign prostatic hyperplasia. Analysis of 5 studies. Doxazosin Study Group. Eur. Urol., 24: 319, 1993.
3. Gillenwater, J. Y., Conn, R. L., Chrysant, S. G., Roy, J., Gaffney, M., Ice, K. and Dias, N. for the Multicenter Study Group: Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: a double-blind, placebo controlled, dose response multicenter study. J. Urol., 154: 110, 1995.
4. Fawzy, A., Braun, K., Lewis, G. P., Gaffney, M., Ice, K. and Dias, N. for the Multicenter Study Group.: Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: a multicenter study. J. Urol., 154: 105, 1995.
5. Chapple, C. R., Carter, P., Christmas, T. J., Kirby, R. S., Bryan, J., Milroy, E. J. G. and Abrams, P.: A three month double-blind study of doxazosin as treatment for benign prostatic bladder outlet obstruction. Brit. J. Urol., 74: 50, 1994.
6. Bendix Holme, J., Cristensen, M. M., Rasmussen, P. C., Jacobsen, F., Nielsen, J., Norgaard, J. P., Olesen, S., Noer, I., Wolf, H. and Husted, S. E.: 29-week doxazosin treatment in patients with symptomatic benign prostatic hyperplasia. A double-blind placebo-controlled study. Scand. J. Urol. Nephrol., 28: 77, 1994.
7. Kaplan, S. A., Soldo, K. A. and Olsson, C. A.: Effect of dosing regimen on efficacy and safety of doxazosin in normotensive men with symptomatic prostatism: a pilot study. Urology, 44: 348, 1994.